Montero Camilo, Torres Rodolfo, Reina Maricely, Flechas Jonth, Andrade David, Moreno Sebastián, Granados Camila, Yomayusa Nancy
Renal Transplant Service - Clínica Universitaria Colombia Colsanitas Keralty Group, Bogotá, Colombia.
Translational research group, Fundación universitaria Sánitas, Bogotá, Colombia.
SAGE Open Med. 2023 Jul 21;11:20503121231187754. doi: 10.1177/20503121231187754. eCollection 2023.
The response to vaccination against the virus that causes severe acute respiratory infection syndrome coronavirus 2 is lower in renal transplant recipients than in the general population. The data obtained from Latin America showed reduced immunogenicity under inactivated virus vaccination schedules and messenger ribonucleic acid platforms.
A retrospective cohort study including renal transplant recipients from Colombia with a two-dose vaccination schedule against severe acute respiratory infection syndrome coronavirus 2 with Pfizer, AstraZeneca, Moderna, Jansen, and Sinovac vaccines between March 1, 2021 and December 1, 2021, was carried out with a follow-up period to evaluate outcomes until May 2022. The outcomes correspond to the titers of immunoglobulin G antibodies against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike and a composite outcome of mortality, general, and intensive care unit hospitalization.
In total, 215 renal transplant recipients with two doses of vaccination for severe acute respiratory infection syndrome coronavirus 2 during the predominance of the Omicron variant in Colombia were included, with the measurement of immunoglobulin G antibody titers against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike at 8 weeks of vaccination. The mean age was 52.1 years, and the standard deviation was ± 14.2; severe acute respiratory infection syndrome coronavirus 2 infection occurred in 20% of the population, of which 23.26% required hospitalization, 13.95% were under intensive care unit management, and four cases of mortality (9.3%) were reported. Of the total population, 52.5% had antibody titers higher than 0.8 IU/mL (median 0.77 IU/mL, interquartile range 0.4-131). Patients with severe acute respiratory infection syndrome coronavirus 2 infection had a median antibody titer of 0.4 IU/mL (interquartile range 0.4-3.45), and those without infection had a median antibody titer of 1.8 IU/mL (interquartile range 0.4-202) ( = 0.015).
Anti-severe acute respiratory infection syndrome coronavirus 2 antibody titers with a cutoff point less than 0.8 IU/mL are associated with increased risk of severe acute respiratory infection syndrome coronavirus 2 infection.
肾移植受者对导致严重急性呼吸综合征冠状病毒2的病毒疫苗接种的反应低于一般人群。来自拉丁美洲的数据显示，在灭活病毒疫苗接种方案和信使核糖核酸平台下免疫原性降低。
进行了一项回顾性队列研究，纳入了2021年3月1日至2021年12月1日期间在哥伦比亚接受两剂辉瑞、阿斯利康、莫德纳、杨森和科兴疫苗接种以预防严重急性呼吸综合征冠状病毒2的肾移植受者，并进行随访以评估直至2022年5月的结局。结局包括针对严重急性呼吸综合征冠状病毒2刺突蛋白受体结合域的免疫球蛋白G抗体滴度以及死亡率、普通住院和重症监护病房住院的综合结局。
总共纳入了215名在哥伦比亚奥密克戎变异株占主导期间接受两剂严重急性呼吸综合征冠状病毒2疫苗接种的肾移植受者，在接种疫苗8周时测量了针对严重急性呼吸综合征冠状病毒2刺突蛋白受体结合域的免疫球蛋白G抗体滴度。平均年龄为52.1岁，标准差为±14.2；20%的人群发生了严重急性呼吸综合征冠状病毒2感染，其中23.26%需要住院治疗，13.95%在重症监护病房接受管理，报告了4例死亡病例（9.3%）。在总人口中，52.5%的抗体滴度高于0.8 IU/mL（中位数0.77 IU/mL，四分位间距0.4 - 131）。发生严重急性呼吸综合征冠状病毒2感染的患者抗体滴度中位数为0.4 IU/mL（四分位间距0.4 - 3.45），未感染患者的抗体滴度中位数为1.8 IU/mL（四分位间距0.4 - 202）（P = 0.015）。
截断值低于0.8 IU/mL的抗严重急性呼吸综合征冠状病毒2抗体滴度与严重急性呼吸综合征冠状病毒2感染风险增加相关。
